Company Of The Day: Johnson & Johnson
What?
Countries in the European Union placed an order for approximately 37 million Covid-19 vaccine doses from Johnson & Johnson (NYSE:J&J), adding to the E.U’s initial order of 200 million doses.
So What?
- Will Johnson & Johnson Stock Rebound To Its Pre-Inflation Shock Highs of $185?
- Should You Pick Johnson & Johnson Stock At $160?
- Should You Pick Johnson & Johnson Stock After A 6% Fall In A Month Despite Upbeat Q3?
- What’s Happening With Johnson & Johnson Stock?
- Johnson & Johnson Poised For A Muted Q2?
- Cross-Sector Comparison: Is Caterpillar Stock A Better Pick Over J&J?
While the bloc had the option to buy an additional 100 million doses, the current orders are just about a third of that number. Countries are likely reluctant to double down on the shot, as J&J has faced significant production problems, shipping just about 15 million doses to the E.U. in Q2, well below an anticipated 55 million.
See Our Complete Analysis For Johnson & Johnson
What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market since 2016
See all Trefis Price Estimates and Download Trefis Data here
What’s behind Trefis? See How It’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams